Articles tagged "IVIG"

2016 American Transplant Congress
Donor Specif Antibody (DSA) Kinetics in Patients with Antibody Mediated Rejection (AMR) Treated with Plasmapheresis and Bortezomib.
L. Requião-Moura,¹ M. Afonso,² A. Sakashita,³ M. Silva,¹ A. Matos,¹ A. Pacheco-Silva.¹
¹Kidney Transplant, Hospital Israelita Albert Einstein, São Paulo, Brazil; ²Histocompatibility Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil; ³Blood Bank, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Backgroud: The best choice to treat AMR is not supported by several evidences, and recently the interest in drugs as Bortezomib has improved. Aim: Evaluted…
2016 American Transplant Congress
Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.
M. Tseng,¹ S. Ge,¹ R. Roberts,² C. Kuo,² J. Choi,¹ N. Nissen,¹ M. Chu,¹ I. Kim,¹ B. Shin,¹ M. Toyoda,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pediatrics & Immunology, UCLA, Los Angeles, CA.
Introduction: Monoclonal antibodies that disrupt CD40/CD40 ligand (CD40L) interactions are likely to have utility in human transplantation. However, the extent of the immunosuppressive effects of…
2016 American Transplant Congress
The Preventive and Therapeutic Effect of Immunoglobulin on Infectious Complications in Donation After Cardiac Death Liver Transplant Recipients: A Prospective Randomized Controlled Study.
A. Yang, Z. Guo, W. Ju, Y. Chen, M. Han, X. Wang, D. Wang, Y. Ma, A. Hu, X. Zhu, X. He.
Organ Transplantation Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Aims: To prospectively investigate the preventive and therapeutic effect of immunoglobulin on infectious complications in DCD liver transplant recipients, and synthetically evaluate its influence on…
2016 American Transplant Congress
Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.
T. Sievers, J. Thompson, J. Lake.
Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN.
IntroductionThe hypothesis of this study was that the long-term outcomes in liver transplant (LTx) patients with hepatitis B virus (HBV) who were treated with nucleos(t)ide…
2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2015 American Transplant Congress
Donor Selection and Prophylactic IVIg for Induction Immunosuppression Improves Outcomes for HIV+ Kidney Transplant Recipients (HIV+ Tx)
G. Malat,^1,2 L. Panarey,³ A. Sharma,³ K. Ranganna,³ D. Reich,² G. Xiao,² A. Doyle.³
¹Dept of Pharmacy, Hahnemann University Hospital, Philadelphia; ²Dept of Surgery, Drexel University College of Medicine, Philadelphia; ³Dept of Medicine, Drexel University College of Medicine, Philadelphia, PA.
HIV+ Tx recipients are noted to have higher rates of allorecognition through cellular and humoral mediated pathways. Since 2010, our program instituted IVIg use as…
2015 American Transplant Congress
The Impact of Therapy On the Inflammatory Infiltrate in Renal Allografts With Acute and Chronic Antibody Mediated Rejection
W. Mulley,^1,2 D. Nikolic-Paterson,^1,2 A. Longano,³ Y. Han,¹ F. Ma,¹ J. Kanellis,^1,2 S. Ramessur.^1,2
¹Department of Nephrology, Monash Health, Clayton, Vic, Australia; ²Department of Medicine, Monash University, Clayton, Vic, Australia; ³Department of Pathology, Monash Health, Clayton, Vic, Australia.
Little is known about the effect of usual treatment for acute and chronic antibody mediated rejection (aAMR and cAMR) on inflammatory cells within the allograft.…
2015 American Transplant Congress
Incidence and Clinical Severity of Hypogammaglobulinemia (Hypo-IgG) in Highly-HLA Sensitized Patients (HS) Undergoing Desensitization (DES)
A. Vo,¹ S. Ge,² A. Petrosyan,² M. Toyoda,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA; ²Transplant Immunology Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: Desensitization therapies (DES) have dramatically improved rates of transplantation among HS patients. However, antibody-reduction and B-cell/plasma cell directed therapies could have implications for humoral…
2015 American Transplant Congress
Intermittent High Dose Intravenous Immunoglobulin as Treatment for Donor Specific Antibodies in Renal Transplant Recipients
P. Bolin,¹ K. Parker,² F. Rana,¹ W. Bryant,¹ P. Jawa,¹ R. Harland.³
¹Internal Medicine, East Carolina University, Brody School of Medicine, Greenville, NC; ²Vidant Medical Center, Greenville, NC; ³Surgical Immunology and Transplantation, East Carolina University, Brody School of Medicine, Greenville, NC.
Background: Donor-specific HLA antibody (DSA) formation in post-renal transplant patients is associated with chronic rejection and graft failure. Previous studies in our population have indicated…